Market Overview

Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating

Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars.

The British pharmaceutical company rallied on Tuesday on the release of positive data from their drug Epidiolex.

Related Link: GW Pharmaceuticals Surrenders Big Pre-Market Gains

Overall though, sentiment on Vetr is bearish. Less than 2 percent of Vetr users are holding it in their watch-lists, and 57 percent of the crowd's ratings are bearish. The Vetr crowd sees a price target of $89.66, compared to analyst projections $131.25.

See how Vetr's crowdsourced ratings can help you beat the market.

At time of writing, GW Pharma was up 1.64 percent at $93.07.

Latest Ratings for GWPH

Nov 2019MaintainsOverweight
Oct 2019Initiates Coverage OnBuy
Oct 2019Initiates Coverage OnBuy

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Downgrades Health Care Crowdsourcing Analyst Ratings Trading Ideas General


Related Articles (GWPH)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Is London's Coveted Title As Europe's Most Important Financial Hub Up For Grabs?

Celgene To See Major Upside In 2017, Says Canaccord